<DOC>
	<DOCNO>NCT01078610</DOCNO>
	<brief_summary>Safety effectiveness , quality life work productivity Humira patient psoriatic arthritis clinical routine .</brief_summary>
	<brief_title>Safety Effectiveness Effect Quality Life Work Productivity Humira Patients With Psoriatic Arthritis Clinical Routine</brief_title>
	<detailed_description>The primary objective Non-Interventional Study explore therapeutic success , measure improvement follow target variable ( regard respective baseline value ) : - The number miss work day - The self-assessed workability - The severity clinical symptom ( number tender swollen joint , C-reactive Protein erythrocyte sedimentation rate respectively ; total score Disease Activity Score 28 , Psoriasis Area Severity Index ) - The severity functional impairment ( Health Assessment Questionnaire ) - The health-related quality life . All patient disease characteristic document baseline evaluate additional impact target variable ( therapeutic success ) . Particularly impact previous biologic therapy clinical target variable evaluate . The secondary objective document therapeutic success follow variable : - The number physician visit - The number duration hospitalization - The number day impairment non-occupational activity - Pain , exhaustion/fatigue - The reduction number dose concomitant medication - Patient 's assessment adalimumab therapy compare previous therapy . Target parameter safety evaluation adalimumab : - The evaluation safety tolerability documentation analysis serious adverse event ( SAEs ) adverse event ( AEs ) - Evaluation safety tolerability subgroup patient common frequent concomitant disease , especially diabetes type II , cardiovascular , liver , renal insufficiency , relate concomitant medication .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Active progressive psoriatic arthritis adult insufficient response prior basic therapy Hypersensitivity drug one ingredient Active tuberculosis severe infection ( e.g . sepsis opportunistic infection ) Moderate severe cardiac insufficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Long-term Observation</keyword>
	<keyword>Humira</keyword>
	<keyword>Safety</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Work Productivity</keyword>
</DOC>